Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

ASP-8374

Generic Name: ASP-8374

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

ASP8374 + Cemiplimab in Recurrent Glioma

Phase 1

Active, not recruiting

Posted: 2021/04/01

Sponsor:Dana-Farber Cancer I...

ID:NCT04826393

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2019/05/10

Sponsor:Astellas Pharma Inc

ID:NCT03945253

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1

Completed

Posted: 2017/08/24

Sponsor:Astellas Pharma Glob...

ID:NCT03260322

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

GSK and iTeos Terminate TIGIT Cancer Drug Development After Phase 2 Failure

11 days ago

GSK and iTeos Therapeutics have discontinued development of belrestotug, their TIGIT-targeting immunotherapy, after it failed to significantly delay tumor progression in non-small cell lung cancer patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy